Residency · Residency · Internal Medicine

Antimicrobial Stewardship: De-escalation, Duration, and Resistance

Start here

Hey, I know it's late, and you’re probably juggling six admissions and a coding patient, so let’s get straight to the point about antibiotics. Think of it like this: that broad-spectrum antibiotic you just ordered for Mrs. Smith’s suspected pneumonia? It's a powerful tool, but it's also like using a sledgehammer to crack a walnut if we don't refine it. Our job isn't just to start antibiotics; it's to manage them smartly, which we call antimicrobial stewardship. This means thinking about the "5 D's": ensuring a solid Diagnosis, picking the right Drug and Dose, determining the shortest effective Duration, and actively De-escalating. The goal? Get Mrs. Smith better with the least collateral damage to her gut microbiome and to the global fight against superbugs.

Two days from now, when those culture results for Mrs. Smith come back, your pager will undoubtedly be going off for something else entirely. But that's your golden opportunity for an "antibiotic time-out." Did those blood cultures grow Klebsiella pneumoniae that's susceptible to ceftriaxone? Great. That broad-spectrum piperacillin-tazobactam you started can likely be narrowed down. This isn't just academic; it means fewer side effects for Mrs. Smith and less pressure on our antibiotic arsenal. And when she's stable, afebrile, and eating, think about how quickly you can switch her from IV to an oral antibiotic—many of them have excellent bioavailability.

The clock is always ticking for Mrs. Smith, and for all our patients. For most common infections, like community-acquired pneumonia or uncomplicated urinary tract infections, the evidence overwhelmingly supports shorter courses of antibiotics than we might intuitively think. Defaulting to these shorter, evidence-based durations is crucial. Remember, every extra day of antibiotics, especially broad-spectrum ones, increases the risk of Clostridioides difficile infection and fosters resistance, creating more problems down the line for future patients. So, think "short and sweet," and always be ready to de-escalate or stop when the clinical picture allows.

Introduction

Antimicrobial resistance is one of the greatest threats to global health. Antimicrobial stewardship programs (ASPs) aim to optimize antibiotic use by selecting the right drug, dose, and duration to improve patient outcomes while minimizing resistance, adverse effects, and cost. Every internist is a steward of antibiotics at the bedside.

Principles of Antimicrobial Stewardship

Core Strategies

• Prospective audit and feedback: infectious disease review of antibiotic orders with recommendations
• Formulary restriction and preauthorization: requiring approval for certain broad-spectrum agents
• Antibiotic time-outs: structured reassessment at 48-72 hours after culture data returns
• De-escalation: narrowing spectrum based on culture and susceptibility results
• IV-to-oral conversion: transitioning to equivalent oral agents when clinically appropriate

The 5 D's of Antimicrobial Stewardship

• Diagnosis: Is there truly an infection requiring antibiotics?
• Drug: Is this the right antibiotic for the pathogen?
• Dose: Is the dose optimized for the site and severity?
• Duration: What is the shortest effective course?
• De-escalation: Can the spectrum be narrowed?

De-escalation in Practice

When and How to De-escalate

• Review culture and sensitivity results at 48-72 hours and narrow therapy
• Switch from empiric broad-spectrum agents to targeted, narrow-spectrum antibiotics
• Example: vancomycin + piperacillin-tazobactam started empirically; blood cultures grow MSSA; de-escalate to cefazolin
• De-escalation does not increase mortality and may reduce adverse effects and resistance

Common De-escalation Opportunities

• MSSA bacteremia: vancomycin to cefazolin or nafcillin (superior outcomes with beta-lactams)
• Susceptible Enterobacterales: carbapenems to ceftriaxone or fluoroquinolones
• Culture-negative sepsis improving clinically: discontinue antibiotics if no source identified
• Negative procalcitonin trend: supports antibiotic discontinuation in lower respiratory infections

Duration of Therapy: Evidence-Based Shorter Courses

Conditions Where Shorter Courses Are Supported

• Community-acquired pneumonia: 5 days (if clinically stable for 48 hours); no benefit to 7-10 days
• Uncomplicated urinary tract infection: 3-5 days for cystitis; 5-7 days for pyelonephritis with fluoroquinolones
• Intra-abdominal infection with adequate source control: 4 days (STOP-IT trial)
• Uncomplicated cellulitis: 5-6 days if clinically improving
• Hospital-acquired/ventilator-associated pneumonia: 7 days (unless non-fermenting gram-negatives)
• Uncomplicated gram-negative bacteremia: 7 days (BALANCE trial)

Tools to Guide Duration

• Procalcitonin: serial levels guide antibiotic discontinuation in pneumonia and sepsis
• Clinical stability criteria: afebrile, improving WBC, tolerating oral intake, hemodynamically stable
• Longer courses remain appropriate for endocarditis, osteomyelitis, and undrained abscesses

Antimicrobial Resistance

Key Resistance Patterns

• MRSA: methicillin-resistant Staphylococcus aureus; treat with vancomycin, daptomycin, or linezolid
• ESBL-producing Enterobacterales: extended-spectrum beta-lactamase producers; carbapenems are treatment of choice
• CRE: carbapenem-resistant Enterobacterales; ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol
• VRE: vancomycin-resistant Enterococcus; linezolid or daptomycin
• Pseudomonas aeruginosa: intrinsic resistance to many agents; always confirm susceptibilities
• Clostridioides difficile: consequence of broad-spectrum antibiotic use; fluoroquinolones and clindamycin are highest risk

Risk Factors for Resistant Organisms

• Prior antibiotic exposure within 90 days
• Recent hospitalization or nursing facility residence
• Indwelling devices (catheters, lines)
• International travel (ESBL colonization)
• Prior culture data showing resistant organisms

Common Stewardship Pitfalls

• Treating asymptomatic bacteriuria (except in pregnancy and pre-urologic procedures)
• Continuing broad-spectrum antibiotics despite negative cultures and clinical improvement
• Using antibiotics for non-infectious diagnoses (e.g., drug fever, gout flare, DVT misdiagnosed as cellulitis)
• Duplicate anaerobic coverage (e.g., metronidazole + piperacillin-tazobactam)
• Failure to adjust for renal or hepatic dysfunction

IV-to-Oral Transition

• Most patients with functioning GI tracts can transition to oral antibiotics early
• High oral bioavailability agents: fluoroquinolones (~100%), linezolid (~100%), TMP-SMX (~95%), metronidazole (~100%), doxycycline (~95%)
• The OPAT (outpatient parenteral antibiotic therapy) model may be avoidable with appropriate oral agents
• POET trial: oral step-down noninferior to IV for left-sided endocarditis in stable patients

Key Clinical Pearls

• Perform an antibiotic time-out at 48-72 hours on every patient receiving empiric antibiotics
• Shorter antibiotic courses are noninferior for most common infections; default to the evidence
• De-escalation to narrow-spectrum agents improves outcomes and reduces C. difficile risk
• Do not treat asymptomatic bacteriuria; positive urine cultures without symptoms are not infections
• Know which oral antibiotics have high bioavailability to facilitate early IV-to-oral switches

References

1. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the IDSA and SHEA. Clin Infect Dis. 2016;62(10):e51-e77.
2. Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection (STOP-IT). N Engl J Med. 2015;372(21):1996-2005.
3. Yahav D, Franceschini E, Koppel F, et al. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia (BALANCE). Clin Infect Dis. 2019;69(7):1091-1098.
4. Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis (POET). N Engl J Med. 2019;380(5):415-424.

For the intern

At 3am, your job is to ensure the right antibiotic is started for true infections, not to perfect stewardship decisions. Start broad empiric coverage if your patient has sepsis or severe infection, obtain blood cultures before antibiotics when possible, and document your clinical reasoning. What can wait until morning rounds: de-escalation decisions, IV-to-oral switches, and antibiotic time-outs. Review cultures and sensitivities with your senior or attending at 48-72 hours—that's when de-escalation happens. If a patient is improving on day three of antibiotics but cultures are negative and an alternative diagnosis emerges (think drug fever or gout misdiagnosed as cellulitis), don't be afraid to stop antibiotics altogether after discussion with your team.

Common pitfalls

• Treating colonization instead of infection: Positive urine cultures without dysuria, frequency, or systemic symptoms are asymptomatic bacteriuria in most patients—don't treat it (exceptions: pregnancy, pre-urologic procedures). A sputum culture growing MRSA in a patient without pneumonia doesn't need vancomycin.
• Continuing empiric broad-spectrum therapy beyond 72 hours: If cultures are negative and the patient is improving, narrow or stop antibiotics. Vancomycin plus piperacillin-tazobactam should rarely continue past culture data without a documented resistant organism or persistent severe sepsis.
• Defaulting to 10-14 day courses reflexively: Most uncomplicated infections need 5-7 days maximum. Community-acquired pneumonia, cellulitis, and uncomplicated bacteremia have strong evidence for shorter durations—challenge yourself to justify why a patient needs more than seven days.
• Forgetting high-bioavailability oral options: Patients eating and drinking can often switch to oral fluoroquinolones, linezolid, or doxycycline rather than remaining on IV therapy or requiring PICC lines for outpatient treatment.

Make it stick

You're covering the floor at 3 AM. A patient spikes a fever, and their white blood cell count is up. Your senior suggests starting broad-spectrum antibiotics. You order blood cultures and initiate vancomycin and piperacillin-tazobactam. This is a crucial, appropriate step in managing potential sepsis. The next morning, you find the blood cultures are growing Staphylococcus aureus, sensitive to cefazolin. This is your cue to de-escalate. You discuss with your attending, and the patient is switched to cefazolin. This seamless transition from empiric, broad-spectrum coverage to targeted, narrow-spectrum therapy based on culture results is the essence of good antimicrobial stewardship.

If you remember one thing

Always perform an "antibiotic time-out" at 48-72 hours, reassessing the need for antibiotics and the opportunity to de-escalate. Default to shorter, evidence-based durations for common infections, as longer courses rarely provide additional benefit and increase risks.

Read this lecture as Markdown